Non-executive director

Quarterly Activities and Cashflow Report

Retrieved on: 
Lunedì, Gennaio 30, 2023
Australian Government, Credit, Corporate governance, ASX, PTSD, Bionomics, Non-executive director, Quarter, ADS, BNC210, Evercore, Credit Suisse, Subjective units of distress scale, Executive, Research, Public, CNS, Mass meeting, Evaluation, Conference, SUDS, ACDT, Annual general meeting, BNO, Fireside chats, Social anxiety disorder, Proportionality (law), United Kingdom, Contract research organization, Fireside, Allosteric regulation, KOL, Data, Social anxiety, American College, Safety, GABAA receptor negative allosteric modulator, Central nervous system, Patient, SAD, Annual report, Pharmaceutical industry, Renewable energy, Health insurance, Animal, Management, MD

Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the financial year ended 30 June 2022.

Key Points: 
  • Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the financial year ended 30 June 2022.
  • On 25 October 2022, Bionomics released the Quarterly Activities Report for the quarter ending September 2022.
  • Finally, with the additional financing activities during the quarter, the Company has sufficient cash runway to support its ongoing activities and upcoming milestones with runway to at least mid-2024.
  • A copy of the full release, including a copy of the ASX Appendix 4C Cashflow Report can be found on the Company's website.

EQS-News: Vulcan Energy Resources Limited: Vulcan achieving further operational advancements

Retrieved on: 
Giovedì, Febbraio 2, 2023
Carbon, Lithium, Demo, HSEQ, VAT, VES, Frankfurt Stock Exchange, National Association of State Directors of Developmental Disabilities Services, HSE, Engineering, Sustainalytics, Map, Sale, Occupational safety and health, JV, VEE, Geothermal energy, FSE, Remuneration, Health, Information economy, Water, ASX, Lithium hydroxide, ESG, Research, GET, Lithium chloride, Insheim, PFS, VUL, Pilot plant, Chemical engineering, Interpretation, City, Quarter, Morning Star, Electrolysis, Heat, Evaluation, DFS, Safety, Area studies, CO2, Ion, Annual report, MVV, ISO, ICP-OES, Electricity, Phase 1, Non-executive director, Renewable energy, Fine chemical, Risk management, Management, Surveying, Bookkeeping, LNG, Stellantis

Vulcan Energy Resources Limited (Vulcan; ASX: VUL, FSE: VUL, the Company) continued to operate its commercial renewable energy plant successfully and deliver on its strategy to develop the Zero Carbon Lithium™ Project during the December 2022 Quarter (“the Quarter”).

Key Points: 
  • Vulcan Energy Resources Limited (Vulcan; ASX: VUL, FSE: VUL, the Company) continued to operate its commercial renewable energy plant successfully and deliver on its strategy to develop the Zero Carbon Lithium™ Project during the December 2022 Quarter (“the Quarter”).
  • Vulcan received approval from the state authority in Rhineland-Pfalz, Germany, for the Operating Plan for Vulcan’s lithium extraction Demonstration Plant (Demo Plant).
  • Vulcan announced it had produced the highest grade, lowest impurity LiOH from its Pilot Plant, located at its commercially operational geothermal renewable energy plant, at its Zero Carbon Lithium™ Project.
  • Vulcan changed its financial year end from June 30th to December 31st, effective from July 1st, 2022.

EQS-News: Vulcan Energy Resources Limited: December Quarterly Activities Report

Retrieved on: 
Giovedì, Febbraio 2, 2023
Carbon, Lithium, Demo, HSEQ, VAT, VES, Frankfurt Stock Exchange, National Association of State Directors of Developmental Disabilities Services, HSE, Engineering, Sustainalytics, Map, Sale, Occupational safety and health, JV, VEE, Geothermal energy, FSE, Remuneration, Health, Information economy, Water, ASX, Lithium hydroxide, ESG, Research, GET, Lithium chloride, Insheim, PFS, VUL, Pilot plant, Chemical engineering, Interpretation, City, Quarter, Morning Star, Electrolysis, Heat, Evaluation, DFS, Safety, Area studies, CO2, Ion, Annual report, MVV, ISO, ICP-OES, Electricity, Phase 1, Non-executive director, Renewable energy, Fine chemical, Risk management, Management, Surveying, Bookkeeping, LNG, Stellantis

Vulcan Energy Resources Limited (Vulcan; ASX: VUL, FSE: VUL, the Company) continued to operate its commercial renewable energy plant successfully and deliver on its strategy to develop the Zero Carbon Lithium™ Project during the December 2022 Quarter (“the Quarter”).

Key Points: 
  • Vulcan Energy Resources Limited (Vulcan; ASX: VUL, FSE: VUL, the Company) continued to operate its commercial renewable energy plant successfully and deliver on its strategy to develop the Zero Carbon Lithium™ Project during the December 2022 Quarter (“the Quarter”).
  • Vulcan received approval from the state authority in Rhineland-Pfalz, Germany, for the Operating Plan for Vulcan’s lithium extraction Demonstration Plant (Demo Plant).
  • Vulcan has a renewable heat offtake agreement with MVV, the municipal energy supplier for the City of Mannheim.
  • Please see the Remuneration Report in the 2022 Annual Report for further details on Director’s Remuneration.

Appointment of Dr. David John Jeans CBE as HistoIndex's Non-Executive Chairman

Retrieved on: 
Martedì, Gennaio 10, 2023
Fibrosis, Cancer, Health, Trustee, Drug development, Non-executive director, Cardiff University, Johnson & Johnson, CBE, Growth, Bristol Myers Squibb, Health care, Scottish Science Advisory Council, Army Science Board, Digital health, Francis Crick Institute, Commander, Management, Science

Since the incorporation of the Company, Mr Sim Giok Lak has guided HistoIndex with his wealth of industrial and corporate experiences.

Key Points: 
  • Since the incorporation of the Company, Mr Sim Giok Lak has guided HistoIndex with his wealth of industrial and corporate experiences.
  • Dr. David John Jeans was first appointed to the Board as a non-executive director on 17th May 2022.
  • In 2012, John was awarded the Commander of the Order of the British Empire (CBE) for his significant contributions to Life Sciences, Healthcare and Science.
  • Says John, ''I am excited to be appointed as the Non-Executive Chairman of the Board.

Appointment of Dr. David John Jeans CBE as HistoIndex's Non-Executive Chairman

Retrieved on: 
Martedì, Gennaio 10, 2023
Fibrosis, Cancer, Health, Trustee, Drug development, Non-executive director, Cardiff University, Johnson & Johnson, CBE, Growth, Bristol Myers Squibb, Health care, Scottish Science Advisory Council, Army Science Board, Digital health, Francis Crick Institute, Commander, Management, Science

Since the incorporation of the Company, Mr Sim Giok Lak has guided HistoIndex with his wealth of industrial and corporate experiences.

Key Points: 
  • Since the incorporation of the Company, Mr Sim Giok Lak has guided HistoIndex with his wealth of industrial and corporate experiences.
  • Dr. David John Jeans was first appointed to the Board as a non-executive director on 17th May 2022.
  • In 2012, John was awarded the Commander of the Order of the British Empire (CBE) for his significant contributions to Life Sciences, Healthcare and Science.
  • Says John, ''I am excited to be appointed as the Non-Executive Chairman of the Board.

Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer

Retrieved on: 
Martedì, Dicembre 20, 2022
Biotechnology, Hospitals, Pharmaceutical, Health, PSMA, Eli Lilly and Company, PSCA, Ropes & Gray, Patient, DRS, Social media, Penn, Cooley, Lymphatic system, CAR, University, Invention, Partnership, Cell engineering, EPS, IPR, American Cancer Society, Risk, Centerview Partners, MD, Clinical trial, HIV, ARLA, Non-executive director, Doctor of Philosophy, Gilead Sciences, Hart–Scott–Rodino Antitrust Improvements Act, Research, Cancer, Acquisition, Pharmaceutical industry, Medical imaging, Security (finance), Chewing, Immunotherapy, Medicine, Twitter

Kite, a Gilead Company (Nasdaq: GILD), and Tmunity Therapeutics (Tmunity), today announced that the companies have signed an agreement in which Kite will acquire Tmunity, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.

Key Points: 
  • Kite, a Gilead Company (Nasdaq: GILD), and Tmunity Therapeutics (Tmunity), today announced that the companies have signed an agreement in which Kite will acquire Tmunity, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.
  • As part of Kite’s acquisition, the Tmunity founders will become senior scientific advisors for Kite.
  • Kite will acquire all outstanding shares of Tmunity other than those already owned by Kite.
  • As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company.

EQS-News: Appointment of New Canadian Director

Retrieved on: 
Domenica, Dicembre 18, 2022
Acquisition, HCH, Bachelor of Science, Hot Chili, Platinum, TSX Venture Exchange, Metal, Productora de Software, Cortaderas, ASX, Mining, Copper, News, Area studies, Gold, Remuneration, Imperial, CU, Technical report, Royal School, Royal School of Mines, DTM, Risk, FS, Public expenditure, Non-executive director, Capstone, Imperial Metals, ESG, Chalice, Security (finance), Management, Risk management

Mr Quin’s appointment will be effective once he has obtained an Australian Director Identification Number as required by Australian law and expected to occur by the end of February 2023.

Key Points: 
  • Mr Quin’s appointment will be effective once he has obtained an Australian Director Identification Number as required by Australian law and expected to occur by the end of February 2023.
  • Further, due to the Company’s listing on the TSX Venture Exchange (“TSXV"), the appointment remains subject to approval by the TSXV.
  • Non-executive Chairman Dr Nicole Adshead-Bell commented “We are very pleased to welcome a director of Stephen’s calibre to the Board of Hot Chili.
  • On confirmation of his appointment, Mr Quin will also become a member of the Company’s Audit and Risk, Remuneration and ESG and Nomination Committees.

Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer

Retrieved on: 
Giovedì, Dicembre 15, 2022
Biogen, Corporations Act 2001, Psychiatry, Social anxiety disorder, Employment, Michele Cavion, CNS, ASX, Extraordinary general meeting, School, Public sector, Faculty, EVP, Central nervous system disease, Central nervous system, Vigil, Doctor of Philosophy, Neurology, BNO, Pfizer, SVP, EGM, MD, Neurodegeneration, Corporation, BNC210, Non-executive director, Hotel des Indes (The Hague), Allergan, Appendix (anatomy), Post-traumatic stress disorder, Therapy, FOR, University, Development, Patient, Pharmaceutical industry, Security (finance), Bionomics, Appendix

as President and Chief Executive Officer (CEO), effective 5 January 2023.

Key Points: 
  • as President and Chief Executive Officer (CEO), effective 5 January 2023.
  • Spyros is an experienced biopharmaceutical executive, a recognized neuroscientist/neurologist, and change agent with a 25-year career focused on CNS disorders.
  • Prior to joining Vigil, he served as Chief Development Officer, and SVP, Head of Development at Acadia Pharmaceuticals Inc., CEO at SwanBio Therapeutics, and EVP of Research & Development and Chief Medical Officer at Cavion.
  • The additional options are part of the compensation of Dr. De Souza for his period as Executive Chair of Bionomics.

NEW YORK COMMUNITY BANCORP, INC. COMPLETES ACQUISITION OF FLAGSTAR BANCORP, INC.

Retrieved on: 
Giovedì, Dicembre 1, 2022
Flagstar Bank, Mergers and acquisitions, NYCB, Community Bank, Tripura Merger Agreement, Non-executive director, FBC, SEC filing, FSB, New York Community Bank, Acquisition, Bank, ATM, Annual report, SIX Financial Information, Accounting, Senior, Greater Community Bancorp, NYSE, Risk, Agreement, Sustainability Accounting Standards Board, Plan, Management, Financial services, Security (finance), Flagstar

HICKSVILLE, N.Y., Dec. 1, 2022 /PRNewswire/ -- New York Community Bancorp, Inc. (NYSE: NYCB) (the "Company" or "NYCB") announced that its acquisition of Flagstar Bancorp, Inc. ("Flagstar" or "FBC") was completed earlier today, creating a regional banking franchise ranking among the top 25 banks in the country based on total assets.  In accordance with the Agreement and Plan of Merger dated April 24, 2021, as amended on April 26, 2022 and October 27, 2022 by and among the Company, Flagstar, and 615 Corp. (the "Merger Agreement"), Flagstar merged with and into the Company and Flagstar Bank, FSB now operates as Flagstar Bank, N.A., with New York Community Bank having merged into Flagstar Bank, N.A.

Key Points: 
  • In Flagstar we found a like-minded partner that shares the same values and commitment to our employees, customers, and communities.
  • I am pleased to welcome Flagstar's employees and customers to the New York Community family."
  • Both New York Community and Flagstar will continue to operate their retail banking networks separately under their respective brands.
  • About New York Community Bancorp, Inc.
    New York Community Bancorp, Inc. is the parent company of Flagstar Bank, N.A., one of the largest regional banks in the country.

Rio2 Provides Fenix Gold and Corporate Update

Retrieved on: 
Lunedì, Novembre 28, 2022
FDI, Private sector, QP, Master of Science, Legislation, AIG, National instrument, SEDAR, Disclosure, Organization, State, Project, Social, Employment, RIO, Minister, Risk, Osisko Gold Royalties, Technical report, Growth, Boric acid, Energy, Executive, NI, Government, Treasury, News, EIA, BVL, Public expenditure, Environmental impact assessment, Committee of Ministers of the Russian Empire, Non-executive director, Atacama Region, Gold, Committee, Sale, Quality of life, Sustainability metrics and indices, Investment, Renewable energy, Tourism, Management, Financial services, Risk management, Mining, Economics, Environment

Of the 28 measures being implemented, the following 6 measures are pertinent to Rio2 and its Fenix Gold Project.

Key Points: 
  • Of the 28 measures being implemented, the following 6 measures are pertinent to Rio2 and its Fenix Gold Project.
  • Fenix Gold is working closely with InvestChile to maximize its participation and exposure to the Chilean governments new investment plan.
  • Alex Black continued, I look forward to continuing to work closely with Andrew and the Rio2 and Fenix Gold teams as we navigate the EIA appeal process in preparation for obtaining EIA approval and advancing the Fenix Gold Project to production.
  • Rio2 is focused on taking its Fenix Gold Project in Chile to production in the shortest possible timeframe based on a staged development strategy.